Home Thomson StreetEvents

Travere Therapeutics Inc Pegtibatinase in Classical Homocystinuria Phase 1/2 COMPOSE Study Results Call Transcript

Published May 31, 2023

20 pages (11875 words) — Published May 31, 2023

Price US$ 54.00 | Buy this Report Now

About This Report

Abstract:

Edited Transcript of TVTX.OQ conference call or presentation 31-May-23 12:30pm GMT

Brief Excerpt:

...In addition, any forward-looking statements represent our views as of today, May 31, 2023, and we specifically disclaim any obligation to update such statements to reflect future information, events or circumstances. With that, let me now turn the call over to our Chief Executive Officer, Dr. Eric Dube. Eric M. Dube ...

Report Type:

Transcript

Source:

Thomson StreetEvents

Company:

Travere Therapeutics Inc

Ticker

TVTX.OQ

Time

12:30pm GMT

Format:

PDF

The following is excerpted from the question-and-answer section of the transcript. (Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session) Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Congrats on the data. On the baseline levels, which are already below what you've pointed out as clinically meaningful, the fact that those have declined below 50 micromolar, which you pointed out, is there an additional clinical benefit that you would expect below that threshold? And then given the increasing reduction in total homocysteine, is there an opportunity? Or would it make sense to explore an even higher dose?

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Congrats on the data. On the baseline levels, which are already below what you've pointed out as clinically meaningful, the fact that those have declined below 50 micromolar, which you pointed out, is there an additional clinical benefit that you would expect below that threshold? And then given the increasing reduction in total homocysteine, is there an opportunity? Or would it make sense to explore an even higher dose?

Travere Therapeutics Inc Q3 2023 Earnings Call Transcript – 2023-11-07 – US$ 54.00 – Edited Transcript of TVTX.OQ earnings conference call or presentation 7-Nov-23 9:30pm GMT

Travere Therapeutics Inc FILSPARI in IgA Nephropathy Phase 3 PROTECT Study Results Call Transcript – 2023-09-21 – US$ 54.00 – Edited Transcript of TVTX.OQ conference call or presentation 21-Sep-23 12:30pm GMT

Travere Therapeutics Inc Q2 2023 Earnings Call Transcript – 2023-08-03 – US$ 54.00 – Edited Transcript of TVTX.OQ earnings conference call or presentation 3-Aug-23 8:30pm GMT

Travere Therapeutics Inc at Jefferies Healthcare Conference Transcript – 2023-06-07 – US$ 54.00 – Edited Transcript of TVTX.OQ presentation 7-Jun-23 3:00pm GMT

Travere Therapeutics Inc at William Blair Growth Stock Conference Transcript – 2023-06-06 – US$ 54.00 – Edited Transcript of TVTX.OQ presentation 6-Jun-23 5:40pm GMT

Travere Therapeutics Inc at Bank of America Global Healthcare Conference Transcript – 2023-05-10 – US$ 54.00 – Edited Transcript of TVTX.OQ presentation 10-May-23 10:40pm GMT

Travere Therapeutics Inc Q1 2023 Earnings Call Transcript – 2023-05-04 – US$ 54.00 – Edited Transcript of TVTX.OQ earnings conference call or presentation 4-May-23 8:30pm GMT

Travere Therapeutics Inc Corporate Update Call Transcript – 2023-05-01 – US$ 54.00 – Edited Transcript of TVTX.OQ conference call or presentation 1-May-23 8:30pm GMT

Travere Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript – 2023-04-04 – US$ 54.00 – Edited Transcript of TVTX.OQ presentation 4-Apr-23 7:55pm GMT

Travere Therapeutics Inc at Barclays Global Healthcare Conference Transcript – 2023-03-15 – US$ 54.00 – Edited Transcript of TVTX.OQ presentation 15-Mar-23 3:15pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author

Cite this Report


MLA:	Thomson StreetEvents. "Travere Therapeutics Inc Pegtibatinase in Classical Homocystinuria Phase 1/2 COMPOSE Study Results Call Transcript" May 31, 2023. Alacra Store. May 03, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Travere-Therapeutics-Inc-Pegtibatinase-in-Classical-Homocystinuria-Phase-1-2-COMPOSE-Study-Results-Call-T15619906>

APA:	Thomson StreetEvents. (2023). Travere Therapeutics Inc Pegtibatinase in Classical Homocystinuria Phase 1/2 COMPOSE Study Results Call Transcript May 31, 2023. New York, NY: Alacra Store. Retrieved May 03, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Travere-Therapeutics-Inc-Pegtibatinase-in-Classical-Homocystinuria-Phase-1-2-COMPOSE-Study-Results-Call-T15619906>

US$ 54.00

$ £ €

Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

Example Report

Click to View Sample Report

More Research

Search all our Credit Research from one place.

Travere Therapeutics Inc Pegtibatinase in Classical Homocystinuria Phase 1/2 COMPOSE Study Results Call Transcript

About This Report

Table Of Contents

More from Thomson StreetEvents

About the Author

Cite this Report